Vivos Therapeutics Inc 2026 Annual Report

FORM 10-Q Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. YES☐NO☒ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required tosubmit such files). YES☒NO☐ The registrant has 13,894,600 shares of its common stock, $0.0001 par value per share, outstanding as of May 20, 2026. CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q (this “Report”) contains “forward-looking statements” (as defined in Section 27A of theSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended) that reflect our current expectationsand views of future events. The forward-looking statements are contained principally in the section entitled “Management’s Discussion andAnalysis of Financial Condition and Results of Operations.” Readers are cautioned that known and unknown risks, uncertainties and other You can identify some of these forward-looking statements by words or phrases such as “may,” “will,” “expect,” “anticipate,” “aim,”“estimate,” “intend,” “plan,” “believe,” “is/are likely to,” “potential,” “continue,” “goal” or other similar expressions. We have based theseforward-looking statements largely on our current expectations and projections about future events that we believe may affect our financial ●our ability to successfully integrate SCN business into our operations, including managing staffing, accounting, insurancereimbursement and other challenges; our ability to service the substantial indebtedness we incurred in connection with financing the SCN acquisition; compliance with laws, rules and regulations relating to the corporate practice of medicine; ●our expectations concerning the effectiveness and duration of treatment using our appliances and protocols (which we refer toas The Vivos Method) and the potential for side effects including, but not limited to, patient relapse after completion oftreatment; ●the viability of our current intellectual property and our ability to create and protect new intellectual property in the future;●acceptance of our products and services by the medical and dental communities, as well as the marketplace of the productsand services that we market;●government regulations and our ability to obtain applicable regulatory approvals and comply with both state and federalgovernment regulations including under healthcare laws and the rules and regulations of the FDA and non-U.S. equivalentregulatory bodies;●our ability to hire and retain key employees and other service providers (including dentists, medical doctors or otherhealthcare providers);●the emergence of alternative competing technologies, devices, drugs or other therapies which directly or indirectly impact themarketability of our products and services;●adverse changes in general market conditions for medical devices and the products and services we offer;●our ability to generate cash flow and profitability and continue as a going concern;●our ability to satisfy the criteria for maintaining the listing of our common stock on Nasdaq, which we have faced challengeswith;●our immediate and future financing plans; and●our ability to adapt to changes in market conditions (including volatile and difficult to access capital markets) which couldimpair our operations and financial performance. These forward-looking statements involve numerous risks and uncertainties. Although we believe that our expectations expressed inthese forward-looking statements are reasonable, our expectations may later be found to be incorrect. Our actual results of operations or theresults of other matters that we anticipate herein could be materially different from our expectations. Important risks and factors that couldcause our actual results to be materially different from our expectations are generally set forth in “Management’s Discussion and Analysis ofFinancial Condition and Results of Operations,” “Business” and other sections in this Report as well as the “Risk Factors” section of our The forward-looking statements made in this Report relate only to events or information as of the date on which the statements aremade in this Report. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements,whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence VIVOS THERAPEUTICS INC.Unaudited Condensed Consolidated Statements of Operations(In Thousands, Except Per Share Amounts) VIVOS THERAPEUTICS INC.Notes to Unaudited Condensed Consolidated Financial Statements NOTE 1 - ORGANIZATION, DESCRIPTION AND SIGNIFICANT ACCOUNTING POLICIES Organizatio